Abstract
A recent publication in Science demonstrates the ability of prostate cancer cells to switch lineages from one that is dependent on androgen signaling to a cell type that is not. Known as lineage plasticity, this phenomenon is driven by the transcription factor SOX2 in RB1 and TP53-deficient prostate cancer. SOX2 is a potential prognostic marker and therapeutic target in castration resistant prostate cancer.
Original language | English |
---|---|
Pages (from-to) | 841-842 |
Number of pages | 2 |
Journal | Cancer Biology and Therapy |
Volume | 18 |
Issue number | 11 |
DOIs | |
State | Published - 2 Nov 2017 |
Externally published | Yes |
Keywords
- CRPC
- Lineage plasticity
- RB1
- SOX2
- TP53
- antiandrogen
- prostate cancer